Related references
Note: Only part of the references are listed.Optimal use of bisphosphonates in patients with multiple myeloma
Evangelos Terpos et al.
BLOOD (2013)
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease
Evangelos Terpos et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
Gareth J. Morgan et al.
BLOOD (2012)
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
Maria T. Di Martino et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma
Esperanza Such et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2009)
Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw
Konstantinos Vahtsevanos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450CYP2C8 in multiple myeloma:: a genome-wide single nucleotide polymorphism analysis
Maria E. Sarasquete et al.
BLOOD (2008)
PPARG by dietary fat interaction influences bone mass in mice and humans
Cheryl L. Ackert-Bicknell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma
Ashraf Badros et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Epoxyeicosatrienoic acids, cell signaling and angiogenesis
Ingrid Fleming
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Systematic review: Bisphosphonates and osteonecrosis of the jaws
Sook-Bin Woo et al.
ANNALS OF INTERNAL MEDICINE (2006)
Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors
A Badros et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer
Salvatore Ruggiero et al.
JOURNAL OF ONCOLOGY PRACTICE (2006)
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
A Bamias et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment
RE Marx et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2005)
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
RE Marx
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2003)
Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates
ER van Beek et al.
BONE (2003)
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid
J Wood et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors
ER Van Beek et al.
BONE (2002)
Share Paper
